ASCO 2024 preview – jury still out on AbbVie's cancer push
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
FibroGen throws down the prostate cancer gauntlet
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
Mythic goes back to basics
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
Blueprint still sees an oncology future
Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.
Microbiome make or break time for MaaT Pharma
The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.
Early tests approach for Vincerx’s conjugate revolution
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
Caribou aims to set itself apart from the allogeneic Car-T herd
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
Shattuck gears up for go/no go year
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
Affimed looks to reverse a share price collapse
Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.
